News
XTNT
0.4705
-6.72%
-0.0339
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript
Benzinga · 9h ago
Xtant Medical reports Q1 EPS (2c) vs. 0c last year
TipRanks · 9h ago
Xtant Medical raises FY26 revenue view to $101M-$105M from $95M-$99M
TipRanks · 9h ago
Xtant Medical Updates Q1 Results and Raises 2026 Guidance
TipRanks · 11h ago
Xtant Medical GAAP EPS of -$0.02, revenue of $20.9M, raises FY guidance
Seeking Alpha · 11h ago
*Xtant Medical Holdings Raises 2026 View To Rev $101M-$105M >XTNT
Dow Jones · 11h ago
Xtant Medical Raises FY2026 Sales Guidance from $95.000M-$99.000M to $101.000M-$105.000M vs $96.725M Est
Benzinga · 12h ago
Xtant Medical Hldgs Q1 EPS $(0.02), Inline, Sales $20.884M Beat $20.164M Estimate
Benzinga · 12h ago
Press Release: Xtant Medical Reports First -3-
Dow Jones · 12h ago
Press Release: Xtant Medical Reports First -2-
Dow Jones · 12h ago
*Xtant Medical Holdings 1Q Loss/Shr 2c >XTNT
Dow Jones · 12h ago
*Xtant Medical Holdings 1Q Loss $3.09M >XTNT
Dow Jones · 12h ago
*Xtant Medical Holdings 1Q Rev $20.9M >XTNT
Dow Jones · 12h ago
Weekly Report: what happened at XTNT last week (0504-0508)?
Weekly Report · 2d ago
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
PR Newswire · 6d ago
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
PR Newswire · 05/06 12:00
Weekly Report: what happened at XTNT last week (0427-0501)?
Weekly Report · 05/04 09:52
Xtant Medical Holdings (XTNT) Price Target Increased by 12.12% to 1.26
NASDAQ · 04/28 02:47
Weekly Report: what happened at XTNT last week (0420-0424)?
Weekly Report · 04/27 09:54
More
Webull provides a variety of real-time XTNT stock news. You can receive the latest news about Xtant Medical through multiple platforms. This information may help you make smarter investment decisions.
About XTNT
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.